(NASDAQ: KURA) Kura Oncology's forecast annual revenue growth rate of 69.55% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.79%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.75%.
Kura Oncology's revenue in 2025 is $67,991,000.On average, 5 Wall Street analysts forecast KURA's revenue for 2025 to be $19,900,230,703, with the lowest KURA revenue forecast at $4,882,812,347, and the highest KURA revenue forecast at $37,971,657,718. On average, 6 Wall Street analysts forecast KURA's revenue for 2026 to be $18,384,654,233, with the lowest KURA revenue forecast at $2,744,417,578, and the highest KURA revenue forecast at $39,062,498,774.
In 2027, KURA is forecast to generate $32,101,201,342 in revenue, with the lowest revenue forecast at $4,882,812,347 and the highest revenue forecast at $101,179,836,697.